V

Vanda Pharmaceuticals
D

VNDA

4.55800
USD
0.12
(2.66%)
مغلق
حجم التداول
17,605
الربح لكل سهم
-1
العائد الربحي
-
P/E
-14
حجم السوق
265,804,529
أصول ذات صلة
A
ALKS
1.225
(4.01%)
31.785 USD
AMGN
AMGN
-2.15
(-0.76%)
281.20 USD
BIIB
BIIB
2.500
(2.07%)
123.460 USD
BMRN
BMRN
-0.700
(-1.12%)
61.980 USD
GILD
GILD
0.420
(0.41%)
103.660 USD
INCY
INCY
0.500
(0.81%)
62.500 USD
REGN
REGN
15.98
(2.71%)
606.12 USD
المزيد
الأخبار المقالات

العنوان: Vanda Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.